Cellular ageing could be reprogrammed back towards health, new research finds. A study published in Proceedings of the National Academy of Sciences (PNAS) shows precise modulation of individual transcription factors can reverse core hallmarks of cellular ageing and restore tissue function in vivo. The analysis was led by biotechnology company Junevity,… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s leading story came from a positive development in biopharma, with top companies… Read More
News round-up for 3 – 7 November by Bruno Quinney, Content Team at DDW. This week’s leading story is a positive development in biopharma, with top companies reporting market growth in Q3 of 2025. Elsewhere, new research could help combat yellow fever and weight loss, while £500,000 was awarded to a… Read More
The US Food and Drug Administration (FDA) has approved the first treatment for thymidine kinase 2 deficiency (TK2d), paving the way for landmark treatment options for the mitochondrial disease. Doxecitine and doxribtimine, approved by the FDA, are oral solutions developed by biopharmaceutical company UCB. The powder, also known as Kygevvi, has been approved… Read More
New drug therapies could be developed to prevent hereditary diseases, research reveals. According to a study published in the latest issue of Science, researchers have pinpointed a cellular mechanism involved in the inheritance of genetic mutations. It is believed the findings could help develop treatments… Read More
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) stating its decision not to recommend PTC Therapeutics’ vatiquinone for Friedreich’s ataxia (FA). The FDA stated in the CRL that substantial evidence of efficacy was not demonstrated for vatiquinone and that an additional… Read More
Dox – comprising of doxecitine and doxribtimine – to treat thymidine kinase 2 deficiency (TK2d) has been granted Promising Innovative Medicine (PIM) designation in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA). TK2d is caused by a genetic mutation in the TK2 gene. This… Read More
NRG Therapeutics has been awarded a $5 million grant from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support the development of NRG5051 as a novel disease-modifying treatment for Parkinson’s disease. The company says NRG5051 also has potential in other neurological diseases such as… Read More
Therapies that deliver hydrogen sulphide to cells could one day become the basis of new treatments for obesity and related diseases, new research has concluded. Mounting evidence suggests that hydrogen sulphide plays an important role in the liver. Previous research shows that tiny amounts of hydrogen… Read More
Researchers in Japan have revealed the key underlying mechanisms in muscle atrophy, paving the way towards potential new treatments. While the disuse of muscles is the most frequent catalyst for muscle atrophy, there are several other possible causes, including chronic diseases, injury and exposure to low-gravity… Read More
Researchers at the University of São Paulo (USP) in Brazil and Foresee Pharmaceuticals have tested a synthetic molecule which could increase heart function in patients with heart failure. Heart failure is a condition in which the heart cannot pump enough blood to meet the body’s needs… Read More
Mitochondrial dysfunction is known to play a central role in drug-induced hepatotoxicity, and thus early detection of mitochondrial toxicity is a critical component of initial drug development efforts. While immortalised cell lines are widely used for in vitro assessment of hepatotoxicity, cryopreserved primary human hepatocytes are a preferred model for drug… Read More
Mitochondrial dysfunction is known to play a central role in drug-induced hepatotoxicity, and thus early detection of mitochondrial toxicity is a critical component of initial drug development efforts. While immortalised cell lines are widely used for in vitro assessment of hepatotoxicity, cryopreserved primary human hepatocytes are a preferred model for drug… Read More
Download this new mitochondrial toxicity infographic by Agilent and discover the benefits of novel in vitro strategies for consumer safety. Drug-induced mitochondrial dysfunction has been linked to compound attrition, organ toxicity, black-box warnings, and market withdrawals. The infographic will help you: Gain an historical perspective on mitochondrial… Read More
Download our mitochondrial toxicity infographic and discover the benefits of novel in vitro strategies for consumer safety. Drug-induced mitochondrial dysfunction has been linked to compound attrition, organ toxicity, black-box warnings, and market withdrawals. Our infographic will help you: Gain an historical perspective on mitochondrial toxicity. Understand the importance of testing… Read More
A new webinar is now available to watch anytime. CLN7 neuronal ceroid lipofuscinosis is an inherited lysosomal storage neurodegenerative disease highly prevalent in children. In her webinar, Dr García Macía discusses how failure in autophagy causes the accumulation of structurally and bioenergetically impaired neuronal mitochondria in the… Read More
